Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system - A review

Molecular and Cellular Endocrinology

Volumn 417, Issue , 2015, Pages 1-9

  Vriend, Jerry ^a   Reiter, Russel J ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast cancer; Estrogen receptor; MCF 7; Melatonin; Ubiquitin ligase

Indexed keywords

APC PROTEIN; APOPTOSOME; BRCA1 PROTEIN; CELL CYCLE PROTEIN; E6AP PROTEIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEASOME; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR AP 1; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; APC PROTEIN, HUMAN; BRCA1 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN; UBE3A PROTEIN, HUMAN;

APOPTOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CIRCADIAN RHYTHM; ENZYME SUBSTRATE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MCF 7 CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM;

ADENOMATOUS POLYPOSIS COLI PROTEIN; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MELATONIN; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES;

EID: 84960249470     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.09.001     Document Type: Review

References (118)

1. Alibek K., Kakpenova A., Mussabekova A., Sypabekova M., Karatayeva N. Role of viruses in the development of breast cancer. Infect. Agent. Cancer 2013, 8:32.
2. Anderson S.F., Schlegel B.P., Nakajima T., Wolpin E.S., Parvin J.D. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 1998, 19:254-256.
3. Arbini A.A., Greco M., Yao J.L., Bourne P., Marra E., Hsieh J.T., et al. Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer. Am. J. Pathol. 2011, 178:2367-2376.
4. Aubert C., Janiaud P., Lecalvez J. Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting. J. Neural Transm. 1980, 47:121-130.
5. Balan K.V., Wang Y., Chen S.W., Pantazis P., Wyche J.H., Han Z. Down-regulation of estrogen receptor-alpha in MCF-7 human breast cancer cells after proteasome inhibition. Biochem. Pharmacol. 2006, 72:566-572.
6. Baldwin W.S., Travlos G.S., Risinger J.I., Barrett J.C. Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells. Carcinogenesis 1998, 19:1895-1900.
7. Bertoli C., Skotheim J.M., de Bruin R.A. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell. Biol. 2013, 14:518-528.
8. Blask D.E., Hill S.M. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J. Neural Transm. 1986, S21:433-449.
9. Blask D.E., Pelletier D.B., Hill S.M., Lemus-Wilson A., Grosso D.S., Wilson S.T., et al. Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J. Cancer Res. Clin. Oncol. 1991, 117:526-532.
10. Bornstein G., Bloom J., Sitry-Shevah D., Nakayama K., Pagano M., Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 2003, 278:25752-25757.
11. Castoria G., Migliaccio A., Bilancio A., Di Domenico M., de Falco A., Lombardi M., et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001, 20:6050-6059.
12. Chan C.H., Morrow J.K., Zhang S., Lin H.K. Skp2: a dream target in the coming age of cancer therapy. Cell Cycle 2014, 13:679-680.
13. Chandrasekharan S., Kandasamy K.K., Dayalan P., Ramamurthy V. Estrogen induced concentration dependent differential gene expression in human breast cancer (MCF7) cells: role of transcription factors. Biochem. Biophys. Res. Commun. 2013, 437:475-481.
14. Chen S.Y., Chen C.H. Influences of melatonin on the growth of HELA cells. Yao. Xue. Xue. Bao 2001, 36:641-643.
15. Chen S.T., Choo K.B., Hou M.F., Yeh K.T., Kuo S.J., Chang J.G. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005, 26:1241-1246.
16. Chowdhry S., Zhang Y., McMahon M., Sutherland C., Cuadrado A., Hayes J.D. Nrf2 is controlled by two distinct β-TrCP recognition sites in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 2013, 32:3765-3781.
17. Cini G., Neri B., Pacini A., Cesati V., Sassoli C., Quattrone S., et al. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonin-induced oncostatic effects. J. Pineal Res. 2005, 39:12-20.
18. Cos S., Blask D.E., Lemus-Wilson A., Hill A.B. Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. J. Pineal Res. 1991, 10:36-42.
19. Cos S., González A., Martínez-Campa C., Mediavilla M.D., Alonso-Gonzalez C., Sanchez-Barcelo E.J. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect. Prev. 2006, 30:118-128.
20. Cos S., Martinez-Campa C., Mediavilla M.D., Sanchez-Barcelo E.J. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J. Pineal Res. 2005, 38:136-142.
21. Cos S., Recio J., Sanchez-Barcelo E.J. Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci. 1996, 9:811-816.
22. Cucina A., Proietti S., D'Anselmi F., Coluccia P., Dinicola S., Frati L., et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J. Pineal Res. 2009, 46:172-180.
23. Dagli A., Buiting K., Williams C.A. Molecular and clinical aspects of Angelman syndrome. Mol. Syndromol. 2012, 2:100-112.
24. Dauchy R.T., Xiang S., Mao L., Brimer S., Wren M.A., Yuan L., et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res. 2014, 74:4099-4110.
25. del Río B., García Pedrero J.M., Martínez-Campa C., Zuazua P., Lazo P.S., Ramos S. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J. Biol. Chem. 2004, 279:38294-38302.
26. DeSalle L.M., Pagano M. Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett. 2001, 490:179-189.
27. Easton D.F., Bishop D.T., Ford D., Crockford G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1993, 52:678-701.
28. Fahy B.N., Schlieman M.G., Mortenson M.M., Virudachalam S., Bold R.J. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother. Pharmacol. 2005, 56:46-54.
29. Fan S., Wang J., Yuan R., Ma Y., Meng Q., Erdos M.R., et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999, 284. 1354-1256.
30. Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A., et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
31. Fornas O., Mato M.E., Webb S.M. Antiproliferative effect and cell cycle modulation by melatonin on GH(3) cells. Horm. Res. 2000, 53:251-255.
32. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
33. Fu L., Wang D., Shah W., Wang Y., Zhang G., He J. Association of human papillomavirus type 58 with breast cancer in Shaanxi province of China. J. Med. Virol. 2015, 87:1034-1040.
34. Gery S., Virk R.K., Chumakov K., Yu A., Koeffler H.P. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007, 26:7916-7920.
35. Girgert R., Hanf V., Emons G., Grundker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J. Pineal Res. 2009, 47:23-31.
36. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
37. Hao Z., Huang S. E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Front. Biosci. 2015, 30:474-490.
38. Hashizume R., Fukuda M., Maeda I., Nishikawa H., Oyake D., Yabuki Y. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 2001, 276:14537-14540.
39. Heng B., Glenn W.K., Ye Y., Tran B., Delprado W., Lutze-Mann L., et al. Human papilloma virus is associated with breast cancer. Br. J. Cancer 2009, 101:1345-1350.
40. Hideshima H., Yoshida Y., Ikeda H., Hide M., Iwasaki A., Anderson K.C., et al. IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int. J. Oncol. 2014, 44:1171-1176.
41. Hill S.M., Blask D.E. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res. 1988, 48:6121-6126.
42. Hill S.M., Blask D.E., Xiang S., Yuan L., Mao L., Dauchy R.T., et al. Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J. Mammary Gland. Biol. Neoplasia 2011, 16:235-245.
43. Hill S.M., Belancio V.P., Dauchy R.T., Xiang S., Brimer S., Mao L., et al. Melatonin: an inhibitor of breast cancer. Endocr. Relat. Cancer 2015, 22:R183-R204.
44. Hosey A.M., Gorski J.J., Murray M.M., Quinn J.E., Chung W.Y., Stewart G.E., et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J. Nat. Cancer Inst. 2007, 99:1683-1694.
45. Huibregtse J.M., Scheffner M., Howley P.M., et al. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol. 1993, 13:4918-4927.
46. Inuzuka H., Tseng A., Gao D., Zhai B., Zhang Q., Shaik S., et al. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 2010, 18:147-159.
47. Ishii Y., Papa L., Bahadur U., Yue Z., Aguirre-Ghiso J., Shioda T., et al. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response. Clin. Cancer Res. 2011, 17:2292-2300.
48. Jablonska K., Pula B., Zemia A., Owczarek T., Wojnar A., Rys J., et al. Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. J. Pineal Res. 2013, 54:334-345.
49. Kiefer T., Ram P.T., Yuan L., Hill S.M. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res. Treat. 2002, 71:37-45.
50. Kodadek T., Sikder D., Nalley K. Keeping transcriptional activators under control. Cell 2006, 127:261-264.
51. Korkmaz A., Rosales-Corral S., Reiter R.J. Gene regulation by melatonin linked to epigenetic phenomena. Gene 2012, 503:1-11.
52. Kouzmenko A.P., Takeyama K., Kawasaki Y., Akiyama T., Kato S. Ligand-dependent interaction between estrogen receptor alpha and adenomatous polyposis coli. Genes Cells 2008, 13:723-730.
53. Kudo Y., Guardavaccaro D., Santamaria P.G., Koyama-Nasu R., Latres E., Bronson R., et al. Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol. Cell. Biol. 2004, 24:8184-8194.
54. La Rosa P., Pesiri V., Marino M., Acconcia F. 17β-Estradiol-induced cell proliferation requires estrogen receptor (ER) α monoubiquitination. Cell Signal 2011, 23:78-82.
55. Lai L., Yuan L., Cheng Q., Dong C., Mao L., Hill S.M. Alteration of the MT1 melatonin receptor gene and tis expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res. Treat. 2009, 118:293-305.
56. Lau A.W., Fukushima H., Wei W. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front. Biosci. 2012, 17:2197-2212.
57. Lee E.K., Diehl J.A. SCFs in the new millennium. Oncogene 2014, 33:2011-2018.
58. Li L., Li Z., Howley P.M., Sacks D.B. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 2006, 281:1978-1985.
59. Liao X.H., Lu D.L., Wang N., Liu L.Y., Wang Y., Li Y.Q., et al. Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway. FEBS J. 2014, 281:927-942.
60. Liu L., Zhu Y., Xu Y., Reiter R.J. Melatonin delays cell proliferation by inducing G1 and G2/M phase arrest in a human osteoblastic cell line hFOB 1.19. J. Pineal Res. 2011, 50:222-231.
61. Mao L., Yuan L., Slakey L.M., Jones F.E., Burow M.E., Hill S.M. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res. 2010, 12:R107.
62. Martin V., Herrera F., Carrera-Gonzalez P., García-Santos G., Antolín I., Rodriguez-Blanco J. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res. 2006, 66:1081-1088.
63. Martinez-Campa C., Alonso-Gonzalez C., Mediavilla M.D., Cos S., Gonzalez A., Ramos S., Sanchez-Barcelo E.J., et al. Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J. Pineal Res. 2006, 40:291-296.
64. Martín-Renedo J., Mauriz J.L., Jorquera F., Ruiz-Andrés O., Gonzalez P., Gonzalez-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J. Pineal Res. 2008, 45:532-540.
65. Mediavilla M.D., Cos S., Sanchez-Barcelo E.J. Melatonin increases p53 and p21WAFI expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999, 65:415-420.
66. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
67. Molis T.M., Spriggs L.L., Hill S.M. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol. Endocrinol. 1994, 8:1681-1690.
68. Molis T.M., Spriggs L.L., Jupiter Y., Hill S.M. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J. Pineal Res. 1995, 18:93-103.
69. Moretti R.M., Marelli M.M., Maggi R., Dondi D., Motta M., Limonta P. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol. Rep. 2000, 7:347-351.
70. Muratani M., Tansey W.P. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell. Biol. 2003, 4:192-201.
71. Nah S.S., Won H.J., Park H.J., Ha E., Chung J.H., Cho H.Y., et al. Melatonin inhibits human fibroblast-like synoviocyte proliferation via extracellular signal-regulated protein kinase/P21(CIP1)/P27(KIP1) pathways. J. Pineal Res. 2009, 47:70-74.
72. Nakayama K.I., Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 2006, 6:369-381.
73. Nakayama K., Hatakeyama S., Nakayama K. Regulation of the Cell Cycle at the G1-S Transition by Proteolysis of Cyclin E and p27Kip1. Biochem. Biophys. Res. Commun. 2001, 282:853-860.
74. Narod S.A. BRCA1 and BRCA2 in 2005. Discov. Med. 2005, 5:50-54.
75. Narod S.A., Feunteun J., Lynch H.T., Watson P., Conway T., Lynch J., et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991, 338:82-83.
76. Nawaz Z., Lonard D.M., Dennis A.P., Smith C.L., O'Malley B.W. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1858-1862.
77. Ohta T., Fukuda M. Ubiquitin and breast cancer. Oncogene 2004, 23:2079-2088.
78. Oida K., Matsuda A., Jung K., Xia Y., Jang H., Amagai Y., et al. Nuclear factor-κB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci. Rep. 2014, 4:4057.
79. Patel B.S., Co W.S., Donat C., Wang M., Che M., Prabhala P., et al. Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1. Cancer Biol. Ther. 2015, 16:780-789.
80. Pizarro J.G., Yeste-Velasco M., Esparza J.L., Verdaguer E., Pallas M., Camins A., Folch J. The antiproliferative activity of melatonin in B65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes. J. Pineal Res. 2008, 45:8-16.
81. Prenzel T., Begus-Nahrmann Y., Kramer F., Hennion M., Hsu C., Gorsler T., et al. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res. 2011, 71:5739-5753.
82. Proietti S., Cucina A., Dobrowolny G., D'Anselmi F., Dinicola S., Masiello M.G., et al. Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. J. Pineal Res. 2014, 57:120-129.
83. Proietti S., Cucina A., Reiter R.J., Bizzarri M. Molecular mechanisms of melatonin's inhibitory actions on breast cancer. Cell. Mol. Life Sci. 2013, 70:2139-2157.
84. Rachner T.D., Schoppet M., Niebergall U., Hofbauer L.C. 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. Biochem. Biophys. Res. Commun. 2008, 368:736-741.
85. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 2003, 11:695-707.
86. Reiter R.J., Tan D.X., Manchester L.C., Pilar Terron M., Flores L.J., Koppisepi S. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv. Med. Sci. 2007, 52:11-28.
87. Saha T., Rih J.K., Roy R., Ballal R., Rosen E.M. Transcriptional regulation of the base excision repair pathway by BRCA1. J. Biol. Chem. 2010, 285:19092-19105.
88. Sanchez-Barcelo E.J., Cos S., Fernandez R., Mediavilla M.D. Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer 2003, 10:153-159.
89. Sanchez-Barcelo E.J., Mediavilla M.D., Alonso-Gonzalez C., Rueda N. Breast cancer therapy based on melatonin. Recent Pat. Endocr. Metab. Immune Drug Discov. 2012, 6:108-116.
90. Shabbeer S., Omer D., Berneman D., Weitzman O., Alpaugh A., Pietraszkiewicz A., et al. BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation. Oncogene 2013, 32:5005-5016.
91. Shai A., Pitot H.C., Lambert P.F. E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res. 2010, 70:5064-5073.
92. Shiu S.Y., Li L., Xu J.N., Pang C.S., Wong J.T., Pang S.F. Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. J. Pineal Res. 1999, 27:183-192.
93. Shiu S.Y., Leung W.Y., Tam C.W., Liu V.W., Yao K.M. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and therapy. J. Pineal Res. 2013, 54:69-79.
94. Sigl V., Penninger J.M. RANKL/RANK - from bone physiology to breast cancer. Cytokine Growth Factor Rev. 2014, 25:205-214.
95. Skolnick M.,H., Frank T., Shattuck-Eidens D., Tavtigian S. Genetic susceptibility to breast and ovarian cancer. Pathol. Biol. Paris. 1997, 435:245-249.
96. Song R.X., McPherson R.A., Adam L., Bao Y., Shupnik M., Kumar R., et al. Linkage of rapid estrogen action to MAPK activation by Er α-Shc association and Shc pathway activation. Mol. Endocrinol. 2002, 16:116-127.
97. Srinivasan V., Spence D.W., Pandi-Perumal S.R., Trakht I., Esquifino A.I., Cardinali D.P., et al. Melatonin, environmental light, and breast cancer. Breast Cancer Res. Treat. 2008, 108:339-350.
98. Starita L.M., Parvin J.D. Substrates of the BRCA1-dependent ubiquitin ligase. Cancer Biol. Ther. 2006, 5:137-141.
99. Steven s R.G., Brainard G.C., Blask D.E., Lockley S.W., Motta M.E. Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J. Clin. 2014, 64:207-218.
100. Tamarkin L., Cohen M., Roselle D., Reichert C., Lippman M., Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res. 1981, 41:4432-4436.
101. Tansey W.P. Transcriptional activation: risky business. Genes Dev. 2001, 15:1045-1050.
102. Teixeira C., Reed J.C., Pratt N. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995, 55:3902-3907.
103. Toss A., Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res. 2015, 17:60.
104. Trinh X.B., Sas L., Van Laere S.J., Prove A., Deleu I., Rasschaert M., et al. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncol. Rep. 2012, 27:657-663.
105. VanKlompenberg M.K., Bedalov C.O., Soto K.F., Prosperi J.R. APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer 2015, 15:457.
106. Vriend J., Reiter R.J. Melatonin as a proteasome inhibitor. Is there any clinical evidence?. Life Sci. 2014, 115:8-14.
107. Wang J., Xiao X., Zhang Y., Shi D., Chen W., Fu L., et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J. Pineal Res. 2012, 53:77-90.
108. Wang T.T., Phang J.M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 1995, 55:2487-2489.
109. Wei S., Yang H.C., Chuang H.C., Yang J., Kulp S.K., Lu P.J., et al. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J. Biol. Chem. 2008, 283:26759-26770.
110. Xiang S., Coffelt S.B., Mao L., Yuan L., Cheng Q., Hill S.M. Period-2: a tumor suppressor gene in breast cancer. J. Circadian Rhythms 2008, 6:4.
111. Yao F., Wang G., Wei W., Tu Y., Tong H., Sun A. An autophagy inhibitor enhances the inhibition of proliferation induced by a proteasome inhibitor. Mol. Med. Rep. 2012, 5:84-88.
112. Yang X., Wood P.A., Oh E.Y., Du-Quiton J., Ansell C.M., Hrushesky W.J. Down regulation of circadian clock gene period 2 accelerates breast cancer by altering its daily growth rhythm. Breast Cancer Res. Treat. 2009, 117:423-431.
113. Yde C.W., Emdal K.B., Guerra B., Lykkesfeldt A.E. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res. Treat. 2012, 135:67-78.
114. Yu Z.K., Gervais J.L., Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:11324-11329.
115. Yuan L., Collins A.R., Dai J., Dubocovich M.L., Hill S.M. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol. Cell. Endocrinol. 2002, 192:147-156.
116. Zheng N., Zhang P., Huang H., Liu W., Hayashi T., Zang L., et al. ERα down-regulation plays a key role in silibinin-induced autophagy and apoptosis in human breast cancer MCF-7 cells. J. Pharmacol. Sci. 2015 Jul, 128(3):97-107.
117. Zhou W., Slingerland J.M. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat. Rev. Cancer 2014, 14:26-38.
118. Zhou Y., Yau C., Gray J.W., Chew K., Dairkee S.H., Moore D.H., et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007, 7:59.